LIK066 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Body Mass Index
Conditions
Elevated Body Mass Index
Trial Timeline
Jun 5, 2015 → Apr 4, 2016
NCT ID
NCT02470403About LIK066 + Placebo
LIK066 + Placebo is a phase 2 stage product being developed by Novartis for Elevated Body Mass Index. The current trial status is completed. This product is registered under clinical trial identifier NCT02470403. Target conditions include Elevated Body Mass Index.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03320941 | Phase 2 | Completed |
| NCT03205150 | Phase 2 | Completed |
| NCT03152591 | Phase 2 | Completed |
| NCT03100058 | Phase 2 | Completed |
| NCT02470403 | Phase 2 | Completed |
| NCT01915849 | Phase 1/2 | Completed |
| NCT01407003 | Phase 1/2 | Completed |
Competing Products
12 competing products in Elevated Body Mass Index
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |
| Olpasiran | Amgen | Phase 1 | 32 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 51 |
| Ivabradine | Amgen | Phase 3 | 76 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 30 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 30 |